Ashkan Shoamanesh Shares OCEANIC-STROKE Trial’s Successful Endpoints
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”We are absolutely thrilled to share that the OCEANIC-STROKE trial has successfully met its primary efficacy and safety endpoints.
These landmark findings validate our ability to uncouple pathological thrombus formation from hemostasis—a breakthrough that has the potential to have far more reaching impact in the medical care of patients with cardiovascular disease.
Asundexian now emerges as an established treatment option addressing a major unmet need among the approximately 5 million people worldwide who experience a new non-cardioembolic ischemic stroke each year.
We are profoundly grateful for our partnership with Bayer and for the invaluable contributions of our global network of investigators and study teams whose dedication made OCEANIC-STROKE possible.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Jul 9, 2026, 08:46Jordan Agay: Folate Deficiency in Patients Receiving PARP Inhibitors
-
Jul 9, 2026, 08:29Laura Katz: Is Human Lactoferrin Better Than Bovine Lactoferrin?
-
Jul 9, 2026, 08:17Anziya Sabeer: AI-Driven Non-Invasive Anemia Detection
-
Jul 9, 2026, 07:37Variable Mechanisms of ADAMTS13 Inhibition by Autoantibodies in iTTP – JTH
-
Jul 9, 2026, 07:31DHR-Sponsored Training Programme at ICMR-CRMCH Week 2 – Day 4 – ICMR-NIRBID
-
Jul 9, 2026, 06:03Barbara Adams Krolak: ISTH Launches Global Women’s Health Hub
-
Jul 9, 2026, 05:49Abdul Mannan: A Low Platelet Count is not Always a Bone Marrow Problem
-
Jul 9, 2026, 05:41Julieta Rosales: Management of Tandem Strokes – To Stent or Not to Stent?
-
Jul 8, 2026, 21:30Matthew Gouveia: How VNS-REHAB Is Transforming the Future of Stroke Rehabilitation